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Everolimus immunosuppression in de novo heart transplant 
recipients: What does the evidence tell us now?
Abstract 
The efficacy of everolimus with reduced cyclosporine in de novo heart 
transplant patients has been demonstrated convincingly in 
randomized studies. Moreover, everolimus-based immunosuppression 
in de novo heart transplant recipients has been shown in two 
randomized trials to reduce the increase in maximal intimal thickness 
based on intravascular ultrasound, indicating attenuation of cardiac 
allograft vasculopathy (CAV). Randomized trials of everolimus in de 
novo heart transplantation have also consistently shown reduced 
cytomegalovirus infection versus antimetabolite therapy. In 
maintenance heart transplantation, conversion from calcineurin 
inhibitors to everolimus has demonstrated a sustained improvement in 
renal function. In de novo patients, a renal benefit may only be 
achieved if there is an adequate reduction in exposure to calcineurin 
inhibitor therapy. Delayed introduction of everolimus may be 
appropriate in patients at high risk of wound healing complications, 
e.g. diabetic patients or patients with ventricular assist device. The 
current evidence base suggests that the most convincing reasons for 
use of everolimus from the time of heart transplantation are to slow 
the progression of CAV and to lower the risk of cytomegalovirus 
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infection. A regimen of everolimus with reduced-exposure calcineurin 
inhibitor and steroids in de novo heart transplant patients represents a 
welcome addition to the therapeutic armamentarium. 
Keywords: everolimus, heart transplantation, mTOR inhibitor, de novo, 
CMV, chronic allograft vasculopathy, rejection
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Introduction
The efficacy and safety of the mammalian target of rapamycin 
(mTOR) inhibitor everolimus in heart transplant patients has been 
extensively assessed in a series of trials over the last decade (1). 
There is a considerable body of evidence to indicate that everolimus-
based immunosuppression can permit a marked reduction in 
exposure to cyclosporine (CsA) (1, 2), although robust evidence 
relating to tacrolimus reduction is still awaited. The efficacy of 
everolimus with reduced CsA has been convincingly demonstrated in 
randomized studies of de novo (3-6) and, to a lesser extent, 
maintenance (7, 8) heart transplant patients. However, its use outside 
the context of clinical trials remains largely restricted to maintenance 
patients in whom there is a reason to reduce or discontinue 
calcineurin inhibitor (CNI) exposure or in whom the direct 
antiproliferative properties of the drug are sought (3, 9). Indeed, the 
most frequent clinical trigger for everolimus introduction is declining 
renal function (7, 8, 10-21); less common indications include the 
development of cardiac allograft vasculopathy (CAV) (14, 17, 22), 
malignancy (23) and recurrent rejection (19, 20) under CNI therapy. 
Published experience with de novo use of everolimus in heart 
transplantation in routine clinical practice are currently relatively 
limited (24-29).
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This article reviews the available evidence on the de novo use of 
everolimus, weighing potential issues raised in recent randomized 
trials with the advantages that could be expected from long-term use 
of everolimus-based immunosuppression in heart transplant 
recipients. 
Methodology
Multiple searches of the PubMed database were performed with no 
time or language restrictions using different combinations of the terms 
‘everolimus’, ‘heart’, ‘cardiac’, ‘transplantation’, ‘randomized’ and 
‘mTOR’. The proceedings of the International Society for Heart and 
Lung Transplantation, the American Transplant Congress and the 
European Society for Organ Transplantation congresses during 2010-
2012 were searched for ‘everolimus’ or ‘mTOR’. 
Efficacy of everolimus in de novo heart transplant recipients
The immunosuppressive potency of everolimus in de novo heart 
transplant recipients was first demonstrated in a randomized study by 
Eisen et al, in which everolimus at a fixed dose of 1.5mg or 3.0mg 
was associated with significantly superior efficacy outcomes to 
azathioprine, both in combination with standard-dose CsA (30) (Table 
1). Since then, following evidence from kidney (6, 31) and heart (4) 
transplantation showing that everolimus with reduced-exposure CsA 
offers equivalent efficacy to everolimus with standard-exposure CsA, 
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and the advantage of therapeutic drug monitoring of everolimus (32), 
two randomized trials have assessed the use of everolimus with 
reduced-exposure CsA versus mycophenolate mofetil (MMF) with 
standard-exposure CsA (3, 5) in de novo heart transplant populations. 
Both studies adjusted everolimus trough concentration according to 
pre-specified target ranges, as is now standard practice. Using an 
everolimus target range of 3-8ng/mL, the primary composite efficacy 
endpoint and the incidence of biopsy-proven acute rejection (BPAR) 
were similar in the everolimus and MMF treatment arms at 12 months 
post-transplant in each study (Table 1). Retrospective, single-center 
analyses using everolimus (3-8ng/mL) with reduced CsA have also 
reported similar efficacy to MMF with standard CsA (25, 26) or 
tacrolimus (27, 29), including one series of 49 patients followed up for 
five years post-transplant (26). Higher everolimus exposure levels in 
CNI-treated patients may be inadvisable in view of an increased rate 
of early (<3 months) deaths in the recent A2310 study among patients 
randomized to a target concentration range of 6-12ng/mL (3). Use of 
IL-2 receptor antibody induction in this setting does not appear to be 
associated with safety concerns (28). 
Only one trial has investigated the use of mTOR inhibition within a 
CNI-free regimen for de novo heart transplant patients, in a series of 
20 patients with poor kidney function at time of transplant (GFR 
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<30mL/min/1.73m2) (33). All patients received steroids, six received 
everolimus and 14 received sirolimus; nine received induction therapy. 
Within the mean follow-up of 500 days, by the end of follow-up 11 
patients (55%) had experienced rejection. Such an approach is 
unlikely to become widely adopted except possibly as a temporary 
regimen in patients with significant renal impairment at the time of 
transplant. However, a low CNI regimen with everolimus from time of 
transplant, followed by early CNI withdrawal (≤3 months post-
transplant), may be effective. This option is being explored in the 
SCHEDULE study, where patients either continue or discontinue CsA 
from week 7 post-transplant (NCT01266148). The results of the study 
are awaited with interest. 
Potential advantages for de novo use of everolimus 
Inhibition of CAV 
CAV affects approximately 50% of heart transplant patients within the 
first five years after transplantation (34) and is a significant cause of 
morbidity and mortality (35). It is estimated that 30% of post-transplant 
deaths are caused by CAV (36). CAV is exacerbated by general risk 
factors including dyslipidemia, diabetes and hypertension that are 
highly prevalent in the transplant population, but also by transplant-
specific factors including donor age and gender, ischemia/reperfusion 
injury, allograft rejection, CMV infection and HLA mismatch (37). 
Seite 6 von 40
25.01.2016https://webmail.insel.ch/owa/WebReadyViewBody.aspx?t=att&id=RgAAAAATpEq...
CAV is characterized by endothelial injury and an exaggerated repair 
response, leading to diffuse intimal hyperplasia and luminal stenosis 
that can involve the entire coronary arterial tree. Stenotic 
microvasculopathy, a form of CAV that is also associated with poor 
prognosis (38), is typified by medial or endothelial proliferation (38). 
The antiproliferative effect of mTOR inhibitors, in addition to its 
immunosuppressive action, limits the cellular proliferation of 
endothelial cells and fibroblasts (37, 39, 40) and thus has the potential 
to ameliorate CAV. Preclinical data have confirmed that everolimus 
reduces vascular smooth muscle hyperplasia (41, 42) while in vitro
exposure of human lung fibroblasts from lung transplant recipients to 
subtherapeutic levels of everolimus has been shown to induce a 
potent antiproliferative effect (37). In percutaneous coronary 
interventions, everolimus-eluting stents are used to reduce the risk of 
restenosis by harnessing everolimus-related inhibition of vascular 
smooth muscle cell proliferation and migration, processes which also 
contribute to vascular remodeling in CAV. Everolimus-eluting stents 
result in superior clinical outcomes versus conventional stents (43-45). 
In heart transplantation, pathological evaluation of endomyocardial 
biopsies has shown that everolimus-based immunosuppression is 
associated with reduced biopsy-proven fibrosis as early as four weeks 
post-transplant (46). Intravascular ultrasound (IVUS) measurements 
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of the change in maximal intimal thickness (MIT) from baseline to one 
year post-transplant are predictive of cardiac events in patients with 
CAV (47). Two randomized studies of everolimus in de novo heart 
transplant recipients have included IVUS measurements as part of the 
study protocol, one with standard CsA and MMF in the control arm (3), 
and the other with standard CsA and azathioprine (30)  (Table 2). 
Both studies used the change in MIT from baseline as the primary 
IVUS endpoint, and each showed that the increase was significantly 
smaller in the everolimus-treated patients, by two-fold or more. 
Consistent with this, the secondary endpoint of incidence of CAV 
(defined as ≥0.5mm increase in MIT) was significantly lower in the 
everolimus cohorts (3, 30). In the trial comparing fixed-dose 
everolimus versus azathioprine, follow-up IVUS data from 24 months 
post-transplant showed that the benefit was maintained, although the 
strict IVUS protocol limited the number of patients for whom evaluable 
data were available (48). Other secondary IVUS endpoints also 
demonstrated a significant advantage in the everolimus arms of both 
studies (3, 31, 48). Coronary narrowing measured by IVUS correlates 
with subsequent coronary events (49-51). Four-year follow-up data 
from the randomized trial of everolimus versus azathioprine by Eisen 
et al have indeed confirmed that the more favorable changes in MIT 
and incidence of CAV at one (30) and two years (48) in the everolimus 
treatment arm were associated with a significantly lower rate of major 
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adverse cardiac events versus the azathioprine group (7.9% versus 
13.6%, p=0.033) (52), although the data have not been published in 
full. In contrast, there was no effect on CAV progression in the NOrdic 
Certican Trial In hEart and lung Transplantation (NOCTET) study, in 
which maintenance thoracic transplant patients were randomized at a 
mean of 5.8 years post-transplant to switch to everolimus with 
reduced CsA or remain on standard CsA therapy (53). A virtual 
histology substudy from that trial suggested that plaque composition 
may be adversely affected following conversion in patients who were 
transplanted several years previously (22). 
CMV infection
Development of CMV infection is more frequent following heart 
transplantation compared to other types of solid organ transplant (54). 
The adverse clinical consequences of CMV infection following heart 
transplantation are well-recognized, and include increased risk of 
allograft rejection and infection, accelerated CAV progression and 
higher mortality (55, 56). Evidence from de novo kidney transplant 
populations has confirmed the incidence of CMV infection to be lower 
with mTOR inhibitors generally (57), and with everolimus specifically 
(58, 59), compared to MPA with standard-exposure CNI therapy. 
Similarly, randomized trials of everolimus in de novo heart 
transplantation have consistently shown a low rate of CMV infection 
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(3-5, 30, 60, 61) (Table 3), and comparative trials versus MMF (3, 5, 
60) or azathioprine (30, 61) have each reported a significantly lower 
rate of CMV infection in the everolimus treatment arms (58). Indeed, 
the incidence of CMV infection in de novo heart transplant recipients 
receiving everolimus with reduced-dose CsA appears to be less than 
half that seen with MMF and standard-dose CsA (3, 60). This effect 
cannot be attributed solely to lower CNI exposure, since Zuckermann 
et al observed a similar rate of CMV infection with everolimus and 
standard CsA versus everolimus with reduced CsA (4). Results 
comparing everolimus to MMF were not due to differences in CMV 
prophylaxis between treatment groups, which were similar in both 
arms or in different CMV serostatus for recipients and donors (3, 61). 
There is evidence to suggest that mTOR is essential for CMV 
replication during late phases of the viral cycle (62) which could 
account for the inhibitor effect of everolimus on CMV infection rates. In 
vitro data indicate that mTOR acts through the mTOR complex 1 
pathway to regulate memory T-cell differentiation (63), and that mTOR 
inhibitors exhibit immunostimulatory effects on memory CD8+ T-cells 
(64) that could improve the functional qualities of infection-induced 
memory cells.
Preservation of renal function 
Evidence relating to a renal benefit of everolimus with reduced CNI 
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from time of heart transplantation is less convincing. The bulk of data 
relating to use of everolimus to minimize CNI-related nephrotoxicity 
and protect renal function in heart transplant recipients derives from 
maintenance heart transplant populations: either randomized (8, 65) 
and non-randomized (10, 12-14) studies of everolimus with reduced-
CNI, or non-randomized trials of conversion from CNI to everolimus 
(11, 15-20). Encouragingly, the two randomized trials of CNI reduction 
in maintenance patients (8, 65) have indicated that an improvement in 
renal function versus controls can be achieved after introduction of 
everolimus in patients with GFR between 20 and 60mL/min/1.73m
2
, 
including in patients with poor baseline function (GFR 20-
29mL/min/1.73m
2
), although caution was expressed over the 
introduction of everolimus in patients with pre-existing proteinuria (8). 
In contrast to experience in kidney transplantation (66), the benefit of 
everolimus was seen following conversion up to approximately 4 
years post-transplant (8, 65). Non-randomized, single-center reports 
have indicated that everolimus introduction with CNI withdrawal in 
maintenance heart transplant patients with varying degrees of renal 
deterioration can significantly improve renal function with an 
acceptable efficacy and safety profile (11, 15, 16, 18-20). Such 
evidence has raised interest in de novo use of everolimus-based 
immunosuppression to reduce early CNI-related nephrotoxicity. 
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In de novo heart transplant recipients, the Phase III study in which 
everolimus was administered with standard-exposure CsA showed 
inferior renal function in the everolimus treatment arm compared to 
the azathioprine group (30) (Table 4). This is not unexpected in view 
of the known potentiation of the nephrotoxic effects of the CNI by 
mTOR inhibitors. More surprising was the absence of a renal benefit 
with CsA reduction in a trial of everolimus-treated de novo heart 
transplant patients randomized to reduced- or standard-exposure CsA 
(4) (Table 4). The authors pointed out that there was poor adherence 
to CsA exposure targets, with fewer than half the patients achieving 
target trough concentration. In a post hoc analysis that compared the 
change in serum creatinine from baseline to month 6 among only 
those patients who met the CsA exposure targets, the increase in 
creatinine levels was significantly smaller in the reduced-CsA arm 
(mean 5.5µmol/L versus 31.4µmol/L, p=0.047). Early data indicating 
that renal function would be superior using everolimus with reduced-
CsA versus MMF with standard-exposure CsA (25) have not been 
borne out in two randomized trials (3, 5) (Table 4). Certain limitations 
of the studies may have contributed to this: the A2310 study used 
identical CsA ranges in the everolimus and MMF groups to month 1 
post-transplant (3) while the other trial had an imbalance in renal 
function at baseline which favored the MMF cohort (5), and adherence 
to the planned reduction in CsA exposure was inadequate in both 
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trials. Nevertheless, current data are not fully convincing regarding a 
renal benefit for de novo heart transplant populations who are not 
selected on the basis of poor kidney function at time of transplant. 
One single-center, single-arm prospective study in 20 de novo heart 
transplant patients with significant renal dysfunction at transplant 
(estimated GFR <30mL/min/1.73m
2
) has described outcomes using a 
CNI-free de novo regimen comprising everolimus or sirolimus with 
corticosteroids, with or without induction (33). Mean (SD) estimated 
GFR increased dramatically, from 28 (17)mL/min/1.73m
2
preoperatively to 64 (24)mL/min/1.73m
2
 at month 6, with all four 
patients who had previously required dialysis becoming dialysis-free. 
However, 55% of patients experienced rejection and 50% were 
eventually converted back to CNI therapy due to adverse events. 
While these results are of interest, it seems unlikely that everolimus-
based CNI-free immunosuppression is appropriate from the time of 
heart transplantation unless renal function is very poor. 
Everolimus and malignancy
At present, reduction of malignancy risk is not generally a reason to 
select de novo therapy with everolimus and the evidence base for 
prevention of post-transplant cancer remains relatively limited. 
Everolimus is, however, licensed for the treatment of advanced renal 
and breast tumors at higher doses than in post-transplant 
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immunosuppression, and a preventative role in transplant recipients is 
potentially of considerable interest. Data in heart transplantation are 
sparse, but mTOR inhibitors appear to reduce the rate of new 
malignancies and non-skin solid cancers in kidney transplant patients 
(67) and an observational study in heart transplantation has 
suggested a benefit for development of non-melanoma skin cancers 
(23). MTOR inhibition leads to selective upregulation of epidermal 
Akt1, potentially restricting the effects of tumor-associated changes on 
Akt1 signaling, which could represent a possible mechanism for 
antitumor activity in the epidermis (68). The CERTICOEUR trial 
(NCT00799188) is evaluating the effect of everolimus on the onset of 
new skin cancers in heart transplant patients with recurrent skin 
cancer receiving everolimus and reduced or discontinued CNI therapy 
versus standard CNI therapy. 
Wound complications in de novo transplant recipients
As with all classes of immunosuppressive drugs, the mTOR inhibitors 
are associated with safety concerns. The most salient of these are 
dyslipidemia, peripheral edema, surgical wound complications, 
effusions, mouth ulcers and possibly proteinuria. These have been 
reviewed extensively elsewhere (1, 2, 69), but since wound healing 
and postoperative pericardial and pleural effusions are of particular 
interest in the de novo setting they are considered here. Further data 
Seite 14 von 40
25.01.2016https://webmail.insel.ch/owa/WebReadyViewBody.aspx?t=att&id=RgAAAAATpEq...
are expected from the SCHEDULE and EVERHEART studies when 
results become available. 
Incisional site complications 
Most types of immunosuppressive therapy adversely affect surgical 
wound healing to some extent (70) but the antiproliferative effect of 
mTOR inhibitors on endothelial cells, fibroblasts and smooth muscle 
cells and their antiangiogenic effect has led to particular awareness of 
healing complications with this class. It can be difficult, however, to 
quantify the effect of mTOR inhibition against the background of 
multiple general risk factors and other immunosuppressants in heart 
transplant populations, compounded by variations in reporting 
categories for wound healing complications between trials and 
differences in dosing regimens. A systematic review of randomized 
controlled trials of either sirolimus or everolimus recently concluded 
that the risk of wound complications is increased in patients receiving 
an mTOR inhibitor with CNI therapy (71), but included early trials in 
which large sirolimus loading doses and high exposure levels were 
used with standard-exposure CsA, so its relevance to modern 
regimens is uncertain. 
The largest randomized trial to date in de novo heart transplants, 
which compared everolimus with reduced CsA versus MMF with 
standard CsA (3) observed no significant difference in the incidence of 
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sternal or non-sternal wound dehiscence between the two groups 
(Table 5). The Phase III trial (33) that compared everolimus at a fixed 
dose of 1.5mg or 3.0mg versus azathioprine, both with standard-
exposure CsA, found lymphocele to be significantly more frequent 
with everolimus (4.8% and 4.3% versus 0.9% with azathioprine) but 
the overall rate of all events was low and there were no significant 
differences in the occurrence of wound dehiscence at the sternal site 
or wound complications unrelated to the site of left ventricular assist 
device (69). A pooled analysis of data from 1,009 heart transplant 
patients taking part in three trials (the Phase III trial [31], a randomized 
trial versus MMF [5], and a randomized trial of everolimus with two 
CsA exposure levels [4]) was undertaken to compare the incidence of 
incision-related complications (72). The overall rate of such 
complications was low with all immunosuppressants but highest with 
everolimus (everolimus 12.3%, MMF 7.2%, azathioprine 11.7%), and 
the difference in serious incisional complications approached 
significance versus MMF (everolimus 6.9%, MMF 1.2%, p=0.051). On 
univariate and multivariate analysis, everolimus was not significantly 
associated with incisional complications versus MMF (odds ratio [OR] 
0.567, 95% CI 0.153-2.110, p=0.398) or versus azathioprine (OR 
1.162, 95% CI 0.697-1.937, p=0.565) (72). 
It is possible that the slight delay in introduction of everolimus (up to 
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72 hours post-transplant) in these studies (4, 5, 30), and in the more 
recent A2310 trial (3) may have facilitated adequate early wound 
healing. A longer delay until mTOR initiation (3-7 days) after heart 
transplantation has been suggested (2, 69) but a trial in which kidney 
transplant patients were randomized to immediate or delayed (4 
weeks) introduction of everolimus and which included wound healing 
events as part of the primary endpoint showed no benefit (73). 
Evaluation of delayed introduction of everolimus in heart transplant 
recipients, or an initial low-exposure mTOR inhibitor regimen, is 
ongoing (74). 
Pericardial and pleural effusions 
Pericardial effusion is a frequent occurrence after heart 
transplantation, with moderately to large effusions reported in 
approximately a fifth of recipients (73, 75-77). Mortality and hospital 
stay are unaffected (75-77), although one study suggested an 
association between pericardial effusions and acute rejection (78). 
Comparative randomized trials of everolimus versus MMF (3, 5) and 
versus azathioprine (30) have demonstrated a higher incidence of 
pericardial effusions in everolimus-treated patients although, 
importantly, cardiac tamponade was not more frequent in any of the 
studies (Table 5). The ongoing EVERHEART study in a de novo heart 
transplant population includes pericardial effusion as a pre-specified 
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endpoint (74), and will offer robust data. The risk of pleural effusions 
appears to be unaffected by use of everolimus compared to MMF 
(Table 5). 
Implications for de novo use of everolimus in heart 
transplantation
The current evidence base suggests that the most convincing reasons 
for use of everolimus therapy from the time of heart transplantation 
are (a) to slow the progression of CAV and potentially reduce 
cardiovascular morbidity and mortality, and (b) to lower the risk of 
CMV infection. It would seem appropriate to consider de novo
everolimus-based immunosuppression in recipients of a heart from a 
donor with coronary artery disease, or who are undergoing 
retransplantation following graft loss due to CAV. A good case could 
be made for use of everolimus therapy in CMV-negative heart 
transplant patients at centers where CMV prophylaxis is not standard 
practice, or possibly in recipient-negative, donor-positive transplants 
even where prophylaxis is routine. Based on available evidence, no 
clear renal benefit is observed using everolimus with reduced CsA 
from time of transplant, although poor adherence to planned CsA 
exposure reductions and/or inadequate protocol-specified lowering of 
CsA exposure early post-transplant mean that further exploration may 
be justified. Currently, everolimus is usually reserved for rescue 
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therapy in maintenance heart transplant recipients who develop renal 
deterioration. However, the NOCTET study showed that pre-emptive 
conversion from CNI to everolimus before severe renal insufficiency 
develops can significantly improve renal function in heart transplant 
recipients, particularly when undertaken earlier post-transplant, 
preferably before three years (79, 80). 
Everolimus with complete CNI avoidance from the day of transplant 
may only be appropriate in patients with very poor baseline kidney 
function who are at low risk for rejection (i.e. non-sensitized), and is 
likely to require use of induction therapy. A more cautious approach in 
patients with renal dysfunction may be to initiate everolimus with 
reduced CsA then undertake planned CNI withdrawal, a strategy that 
is being investigated in the ongoing MANDELA trial (NCT00862979). 
A similar strategy is being investigated in the SCHEDULE study, but is 
being applied regardless of baseline renal function. 
It should be pointed out that the evidence base relating to everolimus 
with CNI immunosuppression in de novo heart transplantation relates 
almost exclusively to patients receiving CsA, not tacrolimus. It is 
relevant, however, that experience with sirolimus in combination with 
tacrolimus in de novo recipients has shown the combination to offer 
effective immunosuppression (81). The drug-drug interactions that 
occur between everolimus and CsA are less pronounced with 
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tacrolimus (82) but data from kidney transplantation has shown that 
everolimus significantly decreases tacrolimus oral bioavailability in a 
dose-dependent manner (83) so therapeutic drug monitoring is 
mandatory to prevent low tacrolimus exposure. 
A target everolimus trough concentration range of 3-8ng/mL in de 
novo heart transplant recipients appears optimal when administered in 
combination with CNI therapy (3). Induction with a lymphocyte-
depleting agent such as rabbit ATG in patients receiving an 
everolimus-based regimen with relatively high CsA exposure (as in 
the A2310 trial) should be avoided due to risk of infection-related 
mortality (3) unless there are compelling clinical indications. Where 
everolimus is initiated at the time of heart transplantation, it is not 
known whether delayed introduction (e.g. until wound healing is 
complete) would be beneficial in avoiding incisional wound healing 
complications. While intuitively this is an appealing option, the most 
recent evidence (3) does not suggest that impaired healing is a clinical 
concern, and data from kidney transplantation indicates no benefit in 
delay (68). If wound healing is a concern in high-risk patients (e.g. 
with high body mass index), low everolimus exposure could be a 
possible strategy but has not been investigated. It seems inadvisable 
to initiate everolimus in de novo heart transplant patients in whom 
repeat surgery is anticipated. 
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Other safety concerns with mTOR inhibitors are not specific to the de 
novo situation (1, 2, 64) and are not reviewed here, but it should be 
pointed out that de novo use of everolimus in patients with 
uncontrolled hyperlipidemia or in whom there is a clear 
contraindication to statin therapy would be unwise. 
Conclusion 
The available evidence suggests that use of everolimus in 
combination with reduced-dose CsA and steroids achieves outcomes 
which are comparable to those observed with other triple drug 
regimens currently used in heart transplantation. Such a combination 
is a therapeutic option in de novo heart transplantation in view of 
robust data showing proven non-inferiority for the prevention of acute 
rejection. While more research is awaited about infection rates with 
cytolytic induction in high-risk patients who are receiving CNI and 
everolimus therapy, this does not seem to be a concern in standard-
risk individuals, and IL-2 receptor antibody induction is not associated 
with safety issues in this setting. A benefit for renal function can be 
achieved with everolimus-based immunosuppression if there is an 
adequate reduction in CNI exposure, but a persistently high level of 
proteinuria (>1g/day) after initiation of ACE inhibitor/angiotensin 
receptor blocker therapy contraindicates everolimus-based 
immunosuppression for de novo patients. Use of everolimus has been 
demonstrated to exert a favorable effect on certain important 
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complications following heart transplantation. It may slow the 
progression of CAV, the most limiting factor for long-term survival in 
heart transplant recipients, and several trials have suggested that the 
risk of CMV infection is reduced in patients receiving everolimus from 
the time of heart transplantation. It may be advisable to delay the 
introduction of everolimus until the wound incision has healed in 
patients who are at high risk of infection or healing complications. 
Thus, while total avoidance of CNI therapy in de novo heart transplant 
patients receiving everolimus appears inadvisable, a regimen of 
everolimus with reduced-exposure CNI and steroids from the time of 
transplant represents a welcome addition to the therapeutic 
armamentarium. 
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Table 1. Efficacy outcomes in prospective trials of everolimus in de 
novo heart transplant recipients 
Study Study design Follow-up Treatment N Primary efficacy endpo
Endpoint
Eisen 2012
a
(3)
Randomized 
Multicenter 
Open label
12 months EVR 1.5mg (3-
8ng/mL) 
Reduced CsA 
Steroids 
± Induction 
282 ISHLT grade ≥3A (2R) 
BPAR, acute rejection 
associated with 
hemodynamic 
compromise, graft 
loss/retransplant, 
death, or loss to 
follow-up
MMF 
Standard CsA 
Steroids 
± Induction 
271
Zuckermann 
2011 (4)
Randomized
Multicenter
Open label
6 months EVR (3-8ng/mL)
Reduced CsA
± Induction
99 ISHLT grade ≥3A (2R) 
BPAR, acute rejection 
associated with 
hemodynamic 
compromise, graft 
loss/retransplant, 
death, or loss to 
follow-up
EVR
Standard CsA
± Induction
100
Lehmkuhl 
2009 (5)
Randomized
Multicenter
Open label
12 months EVR (3-8ng/mL)
Reduced CsA 
Steroids 
± Induction
92 ISHLT grade ≥3A (2R) 
BPAR, acute rejection 
associated with 
hemodynamic 
compromise, graft 
loss/retransplant, 
death, or loss to 
follow-up
MMF
Standard CsA 
Steroids 
± Induction
84
Eisen 2003
(30)
Randomized
Multicenter
Double blind
12 months EVR 1.5mg (fixed 
dose)
CsA
Steroids
± Induction
209 ISHLT grade ≥3A 
(2R) BPAR, acute 
rejection associated 
with hemodynamic 
compromise, graft 
loss/retransplant, 
death, or loss to 
follow-up
EVR 3.0mg
CsA
Steroids
± Induction
211
Aza
Standard CsA
Steroids
± Induction
214
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Aza, azathioprine; BPAR, biopsy-proven acute rejection; CsA, 
cyclosporine; EVR, everolimus; ISHLT, International Society for Heart & 
Lung Transplant; MMF, mycophenolate mofetil; NI, non-inferiority 
a
 Data from a discontinued third treatment arm (everolimus 3.0mg) are 
not shown 
b
 ISHLT grade ≥3A (2R)
c 
Primary efficacy endpoint was at 6 months; proportion of patients 
reaching composite endpoint at 12 months was 41.6% in the EVR 1.5mg 
group (p=0.02), 32.2% in the EVR 3.0mg group (p<0.001) vs 52.8% in 
the azathioprine group
d
 At 12 months
Seite 32 von 40
25.01.2016https://webmail.insel.ch/owa/WebReadyViewBody.aspx?t=att&id=RgAAAAATpEq...
Table 2. Intravascular ultrasound (IVUS) outcomes in randomized 
trials of de novo heart transplant patients receiving everolimus 
Aza, azathioprine; CsA, cyclosporine; EVR, everolimus; MMF, 
mycophenolate mofetil; MPA, mycophenolic acid
a
 Data from a discontinued third treatment arm (everolimus 3.0mg) are not 
Study Study design IVUS Treatment n/N
c
Primary IVUS endpoint
Mean (SD)
Eisen 2012
a 
(3) 
Randomized 
Multicenter 
Open label
Baseline
b
12 months
EVR 1.5mg (3-8ng/mL) 
Reduced CsA 
Steroids 
± Induction 
88/282 0.03 (0.05)
MMF 
Standard CsA 
Steroids 
± Induction 
101/271 0.07 (0.11)
Eisen 2003 
(30) 
Vigano 2007 
(48)
Randomized
Multicenter
Double blind
Baseline
b
12 months
EVR 1.5mg (fixed dose)
CsA
Steroids
± Induction
70/209 0.04
EVR 3.0mg
CsA
Steroids
± Induction
69/211 0.03
Aza
Standard CsA
Steroids
± Induction
72/214 0.10
Baseline
b
24 months
EVR 1.5mg (fixed dose)
CsA
Steroids
± Induction
–f 0.07
EVR 3.0mg
CsA
Steroids
± Induction
–f 0.06
Aza
Standard CsA
Steroids
± Induction
–f 0.15
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shown 
b Within six weeks of transplantation 
c
 Patients with evaluable IVUS data / total number of patients 
d
 Mean change in MIT from baseline to IVUS follow-up (12 or 24 months) 
e Cardiac allograft vasculopathy, defined as ≥0.5mm increase in MIT in ≥1 
matched slides 
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Table 3.  CMV infection rates in randomized trials of everolimus in de 
novo heart transplant recipients 
BPAR, biopsy-proven acute rejection; CMV, cytomegalovirus; CsA, 
Study Study design Follow-
up
Treatment N
Endpoint (definition)
Eisen 2012 
(3)
Randomized 
Multicenter 
Open label
a
12 and 
24 
months
EVR 1.5mg 
Reduced CsA 
Steroids 
± Induction 
279 Laboratory 
documentation of 
CMV infection 
(antigenemia-positive 
or PCR positive) at 
month 12
MMF 
Standard CsA 
Steroids 
± Induction 
268
Zuckermann 
2011 (4)
Randomized
Multicenter
Open label
6 months EVR
Reduced CsA
± Induction
99 CMV infection 
(positive antigenemia 
and/or PCR and/or 
seroconversion 
without signs and/or 
symptoms)
EVR
Standard CsA
± Induction
100
Lehmkuhl 
2009 (5) 
Viganò 2010 
(60)
Randomized
Multicenter
Open label
12 
months
EVR
Reduced CsA 
Steroids 
± Induction
92 CMV event of any 
type (reported as 
adverse event, CMV 
infection, laboratory 
evidence, CMV 
syndrome or CMV 
disease)
MMF
Standard CsA 
Steroids 
± Induction
84
Eisen 2003
(30) 
Hill 2007 
(61)
Randomized
Multicenter
Double blind
12 
months
EVR 1.5 mg
CsA
Steroids
± Induction
209 CMV infection in 
D+/R- group with 
CMV prophylaxis
EVR 3.0 mg
CsA
Steroids
± Induction
211
Azathioprine
CsA
Steroids
± Induction
214
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cyclosporine; EVR, everolimus; MMF, mycophenolate mofetil; D, donor; 
R, recipient; PCR, polymerase chain reaction
a
 Data from a discontinued third treatment arm (everolimus 3.0mg) are 
not shown
Seite 36 von 40
25.01.2016https://webmail.insel.ch/owa/WebReadyViewBody.aspx?t=att&id=RgAAAAATpEq...
Table 4. Renal function in randomized trials of everolimus in de novo
heart transplant recipients 
Study Study design Follow-
up
Treatment N
Endpoint Mean (SD)
Eisen 2012 (3) Randomized 
Multicenter 
Open label
a
12 and 
24 
months
EVR 1.5mg 
Reduced CsA 
Steroids 
± Induction 
279 eGFR at month 12 
(mL/min/1·73m
2
) 
59.4 (22.8)
MMF 
Standard 
CsA 
Steroids 
± Induction 
268 64.7 (28.1)
Zuckermann 
2011 (4)
Randomized
Multicenter
Open label
6 months EVR
Reduced CsA
± Induction
99 eGFR (MDRD) at 
month 6 
(mL/min/1.73m
2
)
59.0
(23.2)
EVR
Standard CsA
± Induction
100 59.5
(48.2)
Lehmkuhl 
2009 (5)
Randomized
Multicenter
Open label
12 
months
EVR
Reduced CsA 
Steroids 
± Induction
92 Calculated 
creatinine 
clearance 
(Cockcroft-Gault)
(mL/min) at 12 
months
68.7
(27.7)
MMF
Standard 
CsA 
Steroids 
± Induction
84 71.8
(29.8)
Eisen 2003
(30)
Randomized
Multicenter
Double blind
12 
months
EVR 1.5mg
CsA
Steroids
± Induction
209 Serum creatinine 
at month 12 
(µmol/L)
168
d
EVR 3.0mg
CsA
Steroids
± Induction
211 172
d
Azathioprine
CsA
Steroids
± Induction
214
141
d
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Aza, azathioprine; CsA, cyclosporine; eGFR, estimated GFR; EVR, 
everolimus; MDRD, Modification of Diet in Renal Disease; MMF, 
mycophenolate mofetil 
a
 Data from a discontinued third treatment arm (everolimus 3.0mg) are 
not shown 
b
 The difference in eGFR at month 12 was -5.6mL/min/1.73m
2
, 97.5% 
confidence interval -10·9, -0·2 i.e. the lower limit of the confidence 
interval was below the non-inferiority margin of -10mL/min/1·73m
2 
(p=0·030 for non-inferiority test; p=0·019 for no-difference test)
c
 Predefined analyses to account for missing month 6 creatinine values 
showed significantly lower mean serum creatinine in the reduced CsA vs. 
the standard CsA group (127.3 vs. 145.9 µmol/L, p=0.023, last 
observation carried forward).
d
 Median values
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Table 5. Incidence of incisional complications and effusions in 
prospective trials of everolimus versus MPA in de novo heart 
transplant recipients 
Aza, azathioprine; CsA, cyclosporine; EVR, everolimus; MMF, 
mycophenolate mofetil 
a
 Data from a discontinued third treatment arm (everolimus 3.0mg) are 
Study Study design Follow-up Treatment N Incisional 
complications 
(%)
P value
Eisen 2012
a 
(3) 
Randomized 
Multicenter 
Open label
12 months EVR 1.5mg (3-
8ng/mL) 
Reduced CsA 
Steroids 
± Induction 
282
24.4, 13.3
b
MMF 
Standard CsA 
Steroids 
± Induction 
271
19.4, 13.1
b
Lehmkuhl 
2009 (5)
Randomized
Multicenter
Open label
12 months EVR (3-8ng/mL)
Reduced CsA 
Steroids 
± Induction
92
–
c
MMF
Standard CsA 
Steroids 
± Induction
84
–
c
Eisen 2003
(30)
Zuckermann 
(69)
Randomized
Multicenter
Double blind
12 months EVR 1.5mg 
(fixed dose)
CsA
Steroids
± Induction
209
4.8, 1.4
d P<0.05 for 
lymphocele
EVR 3.0mg
CsA
Steroids
± Induction
211
4.3, 2.4
d
Azathioprine
CsA
Steroids
± Induction
214
0.9, 0.9
d
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not shown 
b Sternal & non-sternal would healing event, as defined by the 
investigator 
c
 No data on incisional complications provided other than wound 
infections (everolimus 6.6%, MMF 8.6%) 
d
 Lymphocele, wound dehiscence at sternal site 
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